This article presents an overview of 5 Micro-Cap Healthcare Stocks Insiders Are Buying. For a detailed overview of such stocks read our article, 10 Micro-Cap Healthcare Stocks Insiders Are Buying.
5. Retractable Technologies Inc (NYSE:RVP)
Number of Hedge Fund Investors: 3
Retractable Technologies Inc (NYSE:RVP) has been seen heavy insider buying activity over the past few weeks. We covered recently that Retractable Technologies Inc’s (NYSE:RVP) CEO and President Thomas J Shaw bought over 6,000 shares of Retractable Technologies Inc (NYSE:RVP) in March.
On April 2 the executive snapped up a whopping 42,044 shares of Retractable Technologies Inc (NYSE:RVP) at$1.10 apiece. Since then the stock is down 6%.
Of the 933 hedge funds tracked by Insider Monkey, three hedge funds had stakes in Retractable Technologies Inc (NYSE:RVP) as of the end of 2023.
4. Anixa Biosciences Inc (NASDAQ:ANIX)
Number of Hedge Fund Investors: 3
Cancer treatment company Anixa Biosciences Inc (NASDAQ:ANIX) is one of the micro-cap stocks corporate insiders are buying. On March 15, 2024, Amit Kumar CEO bought 30,000 shares of Anixa Biosciences Inc (NASDAQ:ANIX) at $3.22 per share. Since then through April 12 the stock is down 14%. The stock also saw insider buying activity earlier this month when on April 9, Lewis H. Titterton Jr., a director at Anixa Biosciences Inc (NASDAQ:ANIX), snapped up 15,009 shares of Anixa Biosciences Inc (NASDAQ:ANIX) at $3.28 per share.
3. Atossa Therapeutics Inc (NASDAQ:ATOS)
Number of Hedge Fund Investors: 5
Breast cancer treatment company Atossa Therapeutics Inc (NASDAQ:ATOS) ranks third in our list of the micro-cap stocks in the healthcare sector with latest insider purchases. On April 10, Jonathan Finn, a director at Atossa Therapeutics Inc (NASDAQ:ATOS), piled into 25,000 shares of Atossa Therapeutics Inc (NASDAQ:ATOS) at $1.77 per share. Since then the stock has lost about 5% in value.
Out of the 933 funds tracked by Insider Monkey, five hedge funds had stakes in Atossa Therapeutics Inc (NASDAQ:ATOS). The most notable stake in Atossa Therapeutics Inc (NASDAQ:ATOS) is owned by Benjamin A. Smith’s Laurion Capital Management which owns a $1.9 million stake in Atossa Therapeutics Inc (NASDAQ:ATOS).
2. Surrozen Inc (NASDAQ:SRZN)
Number of Hedge Fund Investors: 12
Surrozen Inc (NASDAQ:SRZN) is working on treatments for tissue injury by using targeted regenerative antibodies. Tim Kutzkey, a director and 10% owner at Surrozen Inc (NASDAQ:SRZN), bought 193,548 shares at $15.50 per share on April 4. Since then the stock has lost about 9% in value.
As of the end of the last quarter of 2023, 12 hedge funds tracked by Insider Monkey had stakes in Surrozen Inc (NASDAQ:SRZN). Jim Simons’s Euclidean Capital owns a $824,342 stake in Surrozen Inc (NASDAQ:SRZN).
1. AngioDynamics, Inc (NASDAQ:ANGO)
Number of Hedge Fund Investors: 23
AngioDynamics, Inc (NASDAQ:ANGO) is working on treatments for vascular diseases. On April 8, AngioDynamics, Inc’s (NASDAQ:ANGO) CEO James C. Clemmer piled into 10,000 shares of AngioDynamics, Inc (NASDAQ:ANGO) at $6.70 per share. Since then the stock is down 3.6%.
Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below. You can also look at the 10 Underperforming Stocks Insiders are Buying and the Insiders are Piling into These 10 Healthcare Stocks in 2024.
